Uric acid and atrial fibrillation-Cause or other association?-

Circulation Journal

Volumn 76, Issue 3, 2012, Pages 584-585

  Watanabe, Eiichi ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; URIC ACID;

CARDIOVASCULAR RISK; DISEASE ASSOCIATION; EDITORIAL; GENDER; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HUMAN; HYPERTENSION; HYPERURICEMIA; INFLAMMATION; MENOPAUSE; OXIDATIVE STRESS; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ATRIAL FIBRILLATION; FEMALE; HUMANS; MALE; URIC ACID;

EID: 84857538014     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.cj-12-0057     Document Type: Editorial

References (15)

1. Iguchi Y, Kimura K, Aoki J, Kobayashi K, Terasawa Y, Sakai K, et al. Prevalence of atrial fibrillation in community-dwelling Japanese aged 40 years or older in Japan: Analysis of 41,436 non-employee residents in Kurashiki-city. Circ J 2008; 72: 909-913.
2. Chung MK, Martin DO, Sprecher D, Wazni O, Kanderian A, Carnes CA, et al. C-reactive protein elevation in patients with atrial arrhythmias: Inflammatory mechanisms and persistence of atrial fibrillation. Circulation 2001; 104: 2886-2891.
3. Aviles RJ, Martin DO, Apperson-Hansen C, Houghtaling PL, Rautaharju P, Kronmal RA, et al. Inflammation as a risk factor for atrial fibrillation. Circulation 2003; 108: 3006-3010.
4. Watanabe E, Arakawa T, Uchiyama T, Kodama I, Hishida H. Highsensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion. Int J Cardiol 2006; 108: 346-353.
5. Yamashita T, Sekiguchi A, Iwasaki Y, Date T, Sagara K, Tanabe H, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010; 74: 262-270.
6. Dudley SC Jr, Hoch NE, McCann LA, Honeycutt C, Diamandopoulos L, Fukai T, et al. Atrial fibrillation increases production of superoxide by the left atrium and left atrial appendage: Role of the NADPH and xanthine oxidases. Circulation 2005; 112: 1266-1273.
7. Mihm MJ, Yu F, Carnes CA, Reiser PJ, McCarthy PM, Van Wagoner DR, et al. Impaired myofibrillar energetics and oxidative injury during human atrial fibrillation. Circulation 2001; 104: 174-180.
8. Baker JF, Krishnan E, Chen L, Schumacher HR. Serum uric acid and cardiovascular disease: Recent developments, and where do they leave us? Am J Med 2005; 118: 816-826.
9. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
10. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521.
11. Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P. Relation between serum uric acid and risk of cardiovascular disease in essential hypertension: The PIUMA study. Hypertension 2000; 36: 1072-1078.
12. Suzuki S, Sagara K, Otsuka T, Matsuno S, Funada R, Uejima T, et al. Gender-specific relationship between serum uric acid level and atrial fibrillation prevalence. Circ J 2012; 76: 607-611.
13. Fang J, Alderman MH. Serum uric acid and cardiovascular mortality. JAMA 2000; 283: 2404-2410.
14. Letsas KP, Korantzopoulos P, Filippatos GS, Mihas CC, Markou V, Gavrielatos G, et al. Uric acid elevation in atrial fibrillation. Hellenic J Cardiol 2010; 51: 209-213.
15. Liu T, Zhang X, Korantzopoulos P, Wang S, Li G. Uric acid levels and atrial fibrillation in hypertensive patients. Intern Med 2011; 50: 799-803.